A retrospective study on mild-to-moderate AD patients found that encapsulated RES administered orally for 52 weeks reduced the CSF levels of MMP9, but not those of MMP2, MMP3, and MMP10, compared to the placebo group [91]. Here, MMP10 is linked to Alzheimer disease.